Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heartburn Clear all
Completed Not applicable Interventional

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

NCT01733810
View directory record Official record
Conditions
Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
Cessation of Acid Suppressing Medications
Other
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The EndoGastric Solutions TEMPO Trial

NCT01647958
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
EsophyX System with SerosaFuse fasteners, PPI
Device · Drug
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395
View directory record Official record
Conditions
Heartburn, Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251758
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
99
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated May 17, 2010 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

NCT05197413
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Anxiety
Interventions
Arrae bloat supplement
Dietary Supplement
Lead sponsor
Arrae
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects

NCT00336739
View directory record Official record
Conditions
Healthy
Interventions
cinacalcet
Drug
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2007 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370538
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Mobile, Alabama • San Francisco, California • Westlake Village, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients

NCT04120025
View directory record Official record
Conditions
GERD
Interventions
Diaphragm Training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

NCT00149851
View directory record Official record
Conditions
Symptomatic Gastroespohageal Reflux Disease
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
832 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Jun 11, 2026, 2:02 AM EDT
Terminated Not applicable Interventional Results available

Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study

NCT01327963
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Ocala, Florida • Salem, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 11, 2026, 2:02 AM EDT
Completed No phase listed Observational

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

NCT01286194
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jun 11, 2026, 2:02 AM EDT
Not listed Phase 4 Interventional

Folic Acid in Pediatric Inflammatory Bowel Disease

NCT03860012
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Folic Acid
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms

NCT06419231
View directory record Official record
Conditions
Gut Health
Interventions
Butyrate Formulation, Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 11, 2026, 2:02 AM EDT
Not listed Phase 3 Interventional

Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.

NCT01128582
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Insomnia
Interventions
Rozerem (ramelteon), placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
Up to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00255190
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
181
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn

NCT04153552
View directory record Official record
Conditions
Indigestion, Heartburn
Interventions
HLNatural, Inc. Upset Stomach Relief
Dietary Supplement
Lead sponsor
Hawthorne Effect Inc.
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 4 Interventional

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

NCT00206024
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole magnesium (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

NCT00236184
View directory record Official record
Conditions
Heartburn
Interventions
rabeprazole sodium, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
19 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2010 · Synced Jun 11, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

Do Acid Sensing Ion Channels Contribute to Heartburn?

NCT01095133
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn
Interventions
Amiloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Jun 11, 2026, 2:02 AM EDT
Completed No phase listed Observational

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

NCT02629081
View directory record Official record
Conditions
GERD
Interventions
Controls & Cases
Other
Lead sponsor
Loren Laine
Other
Eligibility
21 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jun 11, 2026, 2:02 AM EDT
Not listed No phase listed Observational

Registry of Outcomes From AntiReflux Surgery

NCT02923362
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions
Laparoscopic Fundoplication, LINX Antireflux
Procedure · Device
Lead sponsor
The Heartburn Foundation
Other
Eligibility
21 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Heber Springs, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 11, 2026, 2:02 AM EDT